• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·AEVS.SW
Share

Aevis Victoria SA Stocks

CHF 12.8Last Updated 27.05.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CHF 1.41B

CHF 12.8
Key Takeaways

Risk factor

Significant default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aevis Victoria SA engages in healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. The company operates through Hospitals, Hospitality, Telemedicine, and Real Estate segments. It operates 22 hospitals with 1,496 beds; manages with a total of 941 rooms with a total rentable surface of 188,109 sqm. It also provides telemedicine, and ambulance and day clinic services. In addition, it engages in the patient hotel, better aging, radiology institute, pharmacy, ophthalmology, real estate management, stem cells, cosmetics, and publishing businesses, as well as organizes seminars. The company is headquartered in Fribourg, Switzerland. Aevis Victoria SA is a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA, ove

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of AEVS.SW is 17 and suggests 33% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.05.2026 02:41

Iranian media reported warning strikes on ships attempting to pass Hormuz

29.05.2026 01:39

U.S. stock market hits four records: investors await U.S.-Iran agreement

29.05.2026 00:43

Anthropic has surpassed OpenAI to become the most expensive AI startup. The valuation is close to $1 trillion

29.05.2026 00:08

Anthropic has introduced a new AI model. It can doubt the accuracy of its answers

28.05.2026 23:49

Stocks rebound: investors encouraged by the announcement of the US-Iran deal

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026